Centiva Capital LP cut its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH – Free Report) by 48.7% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 9,144 shares of the medical equipment provider’s stock after selling 8,689 shares during the quarter. Centiva Capital LP’s holdings in Lantheus were worth $1,004,000 as of its most recent SEC filing.
Other large investors have also bought and sold shares of the company. Farallon Capital Management LLC lifted its stake in shares of Lantheus by 53.7% in the 2nd quarter. Farallon Capital Management LLC now owns 2,279,227 shares of the medical equipment provider’s stock valued at $182,999,000 after purchasing an additional 796,000 shares during the period. Point72 Asset Management L.P. bought a new stake in shares of Lantheus during the 2nd quarter valued at $26,794,000. Massachusetts Financial Services Co. MA purchased a new stake in shares of Lantheus in the 3rd quarter worth about $25,955,000. Swedbank AB lifted its position in Lantheus by 40.9% during the 2nd quarter. Swedbank AB now owns 596,400 shares of the medical equipment provider’s stock valued at $47,885,000 after acquiring an additional 173,100 shares during the period. Finally, LSV Asset Management boosted its stake in Lantheus by 27.9% during the second quarter. LSV Asset Management now owns 640,950 shares of the medical equipment provider’s stock worth $51,462,000 after acquiring an additional 139,647 shares in the last quarter. 99.06% of the stock is owned by institutional investors.
Lantheus Price Performance
Lantheus stock opened at $89.34 on Friday. Lantheus Holdings, Inc. has a one year low of $50.20 and a one year high of $126.89. The business’s fifty day moving average is $99.75 and its 200 day moving average is $97.38. The stock has a market capitalization of $6.21 billion, a PE ratio of 14.87 and a beta of 0.45.
Analysts Set New Price Targets
View Our Latest Stock Report on LNTH
About Lantheus
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.
Further Reading
- Five stocks we like better than Lantheus
- The 3 Best Blue-Chip Stocks to Buy Now
- NVIDIA’s Blackwell Chips Set for Arizona Manufacturing by TSMC?
- How to Choose Top Rated Stocks
- Okta: Bullish Signals Suggest a Market Reversal Is Underway
- Differences Between Momentum Investing and Long Term Investing
- BlackRock Makes Waves With $12B Private Credit Acquisition
Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings, Inc. (NASDAQ:LNTH – Free Report).
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.